Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2(+) breast cancer stem-like cells

BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with no effective standard therapy. Breast cancer stem-like cells (BCSCs) in primary TNBCs are reported to be responsible for metastatic spread of the disease and resistance to chemotherapy, but no availabl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Ly, Stanley, Anand, Vivek, El-Dana, Fouad, Nguyen, Khoa, Cai, Yiming, Cai, Shirong, Piwnica-Worms, Helen, Tripathy, Debasish, Sahin, Aysegul A, Andreeff, Michael, Battula, Venkata Lokesh
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970220/
https://ncbi.nlm.nih.gov/pubmed/33722905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001197
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados